National Bank Financial Raises Dream Global REIT (TSE:DRG.UN) Price Target to C$18.00

Share on StockTwits

Dream Global REIT (TSE:DRG.UN) had its price objective lifted by National Bank Financial from C$17.00 to C$18.00 in a report released on Monday morning, BayStreet.CA reports. They currently have an outperform rating on the stock.

Several other equities analysts also recently issued reports on DRG.UN. Canaccord Genuity boosted their price objective on Dream Global REIT from C$15.50 to C$16.50 in a research report on Monday. CIBC boosted their price objective on Dream Global REIT from C$26.00 to C$27.00 in a research report on Monday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of C$18.00.

Shares of TSE DRG.UN opened at C$14.24 on Monday. The company has a current ratio of 0.70, a quick ratio of 0.24 and a debt-to-equity ratio of 74.83. The stock has a 50 day simple moving average of C$14.09 and a 200-day simple moving average of C$13.80. The company has a market cap of $2.75 billion and a PE ratio of 4.76. Dream Global REIT has a 12-month low of C$11.58 and a 12-month high of C$15.44.

Dream Global REIT Company Profile

Dream Global REIT is a real estate investment trust that provides investors with the opportunity to invest in commercial real estate exclusively outside of Canada. Dream Global REIT's portfolio currently consists of approximately 19.9 million square feet of gross leasable area of office, industrial and mixed-use properties across Germany, the Netherlands, Austria and Belgium.

Recommended Story: Economic Reports

Analyst Recommendations for Dream Global REIT (TSE:DRG.UN)

Receive News & Ratings for Dream Global REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dream Global REIT and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Herc  Stock Rating Upgraded by Zacks Investment Research
Herc Stock Rating Upgraded by Zacks Investment Research
TG Therapeutics  Upgraded to “Hold” by BidaskClub
TG Therapeutics Upgraded to “Hold” by BidaskClub
Krystal Biotech  Stock Rating Lowered by BidaskClub
Krystal Biotech Stock Rating Lowered by BidaskClub
Prothena  Rating Lowered to Strong Sell at BidaskClub
Prothena Rating Lowered to Strong Sell at BidaskClub
BidaskClub Lowers Glu Mobile  to Sell
BidaskClub Lowers Glu Mobile to Sell
Amicus Therapeutics  Rating Lowered to Sell at BidaskClub
Amicus Therapeutics Rating Lowered to Sell at BidaskClub


 
© 2006-2019 Zolmax.